274 results on '"Jens Lundgren"'
Search Results
152. The amino acid substitution A376S in the HIV-1 reverse transcriptase connection subdomain confers low-level phenotypic resistance to nevirapine
153. Routine HIV testing in the colposcopy clinic - acceptable and sustainable
154. Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
155. Discontinuing prophylaxis against Pneumocystis carinii pneumonia. Reply
156. Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals?
157. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial
158. THE ROLE OF EICOSANOIDS IN RESPIRATORY MUCUS HYPERSECRETION
159. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study (vol 185, pg 178, 2002)
160. Integrating Clinical Research into Epidemic Response: The Ebola Experience Preface
161. PLATELET ACTIVATING FACTOR (PAF) CAUSES RELEASE OF GLYCOCONJUGATES (GC) FROM FELINE TRACHEAL EXPLANTS BY LIPOXYGENASE ACTIVATION
162. Admission to hospital in the HAART era. The EuroSIDA study
163. CD4 count and viral load changes in response to >= 3-drug therapy in EuroSIDA: Association with clinical disease progression
164. High yield, but variable coverage, of HIV testing for HIV indicator conditions across the UK
165. PCP problems - Controversies 1996
166. Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial
167. Hyaluronic Acid as Early Biomarker of Graft Loss after Liver Transplantation: A Prospective Study
168. Glyc A, a Novel Marker of Inflammation, Predicts Cardiovascular Events in HIV-Positive Patients: Results of SMART Study
169. Initiation of ART early in HIV infection: START to Finish
170. Type of protease inhibitor and low body mass index predict severe and treatment limiting adverse drug reactions in HIV-patients starting protease inhibitor treatment
171. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4(+) T-cell counts
172. PLATELET ACTIVATING FACTOR STIMULATES RESPIRATORY GLYCOCONJUGATE SECRETION FROM FELINE AIRWAYS INVITRO
173. OptTEST programme interventions for indicator condition HIV testing are effective in significantly increasing HIV testing rates in non-specialist healthcare settings across Europe
174. GASTRIN RELEASING PEPTIDE CAUSES GLYCONJUGATE RELEASE FROM FELINE AIRWAY ORGAN-CULTURES
175. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis (vol 11, pg 657, 2006)
176. EFFECTS OF GASTRIN-RELEASING PEPTIDE AND ANALOGS ON GUINEA-PIG NASAL MUCOSAL SECRETION
177. Who benefited most from immediate treatment in START? A subgroup analysis
178. BRADYKININ BINDING-SITES AND EFFECTS ON GLANDULAR SECRETION IN HUMAN INFERIOR TURBINATE NASAL-MUCOSA
179. Association between resistance and CD4-count change in patients on ART with ongoing viraemia
180. HIV-RELATED NON-HODGKINS-LYMPHOMA AMONG EUROPEAN AIDS PATIENTS
181. Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients
182. The rate of accumulation of NNRTI resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA study
183. Cardiac chamber abnormalities and left ventricular mass in people living with HIV and matched uninfected controls assessed by multidetector computed tomography
184. Viral toad changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load
185. ACTIVATION OF PROTEIN-KINASE C IN FELINE TRACHEAL CULTURES LEADS TO CHRONIC GLYCOCONJUGATE RELEASE THROUGH STIMULATION OF EICOSANOID METABOLISM
186. Strengthening Capacity for Response and Research
187. Predicting the effects on resistance of lack of viral load monitoring in resource-limited settings
188. In silico identification of physiochemical properties at mutating positions relevant to reduced susceptibility to amprenavir
189. A randomised phase III study of neutrexim (trimetrexate glucuronate) (TMTX) with leucovorin (LCV) and dapsone (Dap) versus pentamidine (Pent) for treatment of PCP in HIV patients intolerant or refractory to trimethoprim sulfamethoxazole (t/s)
190. XVI. The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis
191. Development of a definition for rapid progression of renal disease in HIV-positive persons
192. Antiretroviral drugs and the risk of myocardial infarction - Reply
193. Decreasing incidence of non-Hodgkin Lymphoma (NHL) in the era of HAART. The EuroSIDA study
194. Long-term effectiveness of recommended boosted PI-based antiretroviral therapy in Europe
195. Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe
196. HIV indicator diseases across Europe study (HIDES I): results from the pilot phase
197. MECHANISMS BY WHICH GLUCOCORTICOSTEROIDS INHIBIT SECRETION OF MUCUS IN ASTHMATIC AIRWAYS
198. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
199. Engaging Communities in Research and Response
200. Medical HIV prevention: science, public health and medical ethics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.